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Bilitranslocase is an organic anion carrier involved in bilirubin and phthalein uptake by the liver. In
rat liver plasma membranes, its function is assayed by recording the electrogenic sulfobromophthalein
movement. This has been found to be inhibited by both cysteine-specific and arginine-specific reagents.
Inhibition is both partial and it occurs to the same extent, i.e. approximately 50 %. The effects are not
additive. Here we describe the mechanism underlying the above observations. It is concluded that
bilitranslocase occurs in two possible states, featured by high and low affinity for the substrates (for
sulfobromophthalein, Km 5 5 ìM and 37 ìM, respectively). Cysteine- or arginine-reactive reagents, by
reacting selectively with the low-affinity form, entrap it and shift the equilibrium between the two forms,
so that, at completion, only the low-affinity form is present. The substrate concentration in the standard
transport assay is 39 ìM, a value at which the modified low-affinity form operates in the range of half-
maximal velocity. This explains both the apparent half-inhibition measured after the chemical treatments
and the lack of additivity. In addition, the substrates are shown to enhance the rate of conversion from
the low-affinity to the high-affinity form of the translocator, thus favouring its high-affinity form under
physiological conditions.
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Bilitranslocase is a carrier protein [1] located selectively at tantly, these data pointed to a specific bilirubin binding by bili-
translocase. Additionally, the inhibitory effects could be com-the sinusoidal domain of the liver cell plasma membrane [2]. As
suggested by an in vivo experiment, it is involved in bilirubin pletely reversed upon removal of the chemical modification.
Once more, and somewhat surprisingly, the same substrates wereuptake by the liver [3]. Both in liposomes [4] and in erythrocyte
ghosts [5], the purified protein has been shown to reconstitute shown to accelerate markedly the recovery to the full activity
[8, 9], again linking the effect to a specific interaction betweenan electrogenic sulfobromophthalein transport, of the uniport
type. In rat liver plasma membrane vesicles an identical type of bilitranslocase and its ligands, notably bilirubin.
In our attempt to gain a mechanistic view of the partial, non-transport has been demonstrated [2] and is entirely related to
purified bilitranslocase [6]. In this system, sulfobromophthalein additive, inhibitory effect brought about by cysteine and arginine
modifications, a more stringent kinetic analysis of the nativetransport has been reported, on a number of occasions, to be
partially inhibited both by sulfhydryl-specific and arginyl-spe- and the modified forms of bilitranslocase in the membrane was
undertaken. Results are presented here that allow us to infer thecific reagents [729]. In either case, the same level of inhibition,
about 50 %, was observed and the effects were not additive [10]. existence of two forms of the carrier, co-existing in equilibrium,
whose interconversion is affected by the substrates.The conclusion was reached that the modified amino acid resi-
dues are closely located on the sulfobromophthalein-carrier pro-
tein so that a modification of that particular domain can produce
MATERIALS AND METHODSsimilar or even identical functional effects. Protection experi-
ments [8, 9] carried out with a variety of substrates, including Rat liver plasma membrane vesicles were obtained as de-
unconjugated bilirubin, conferred specificity to the effects scribed by van Ameslvoort et al. [11]. Throughout this work a
found, in that no indefinite vesicular damage could be called single vesicles pool stored in aliquots under liquid nitrogen was
upon to explain the reduced transport activity ; even more impor- employed. Its qualities were assessed as, and found to be consis-
tent with, those previously described [2].
Correspondence to S. Passamonti, Dipartimento di Biochimica Bio- Stock solutions of the following reagents were used: 2 mM
fisica e Chimica delle Macromolecole, Universita` degli Studi di Trieste, p-hydroxymercuribenzoate (Sigma) in 1mM NaOH; 0.2 M
I-34100 Italy methylglyoxal (Sigma) and 0.1M N-ethylmaleimide (Sigma) in
E-mail: passamon@bbcm.univ.trieste.it 0.1 M Hepes (Sigma) pH 7.4; mercaptoethanol (BDH); 5 %URL: http://www.bbcm (mass/vol.) sulfobromophthalein (Merck) ; 10 mM nicotinic acidAbbreviations. BSP, sulfobromophthalein; C, high-affinity form of (Merck) in 0.1 M Hepes, pH 7.4.bilitranslocase; C*, low-affinity form of bilitranslocase; I, irreversible
Concentration measurements of the following compoundsinhibitor of bilitranslocase, reacting specifically with either cysteines or
were carried out spectrophotometrically: sulfobromophthaleinarginines ; Nbs2, 5,5′-dithio-bis(2-nitrobenzoate); oatp, organic-anion-
transporting peptide. (å580 5 643103 M21 cm21) [2], p-hydroxymercuribenzoate
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(å255 5 4.43103 M21 cm21) [12], N-ethylmaleimide (å305 5
0.623103 M21 cm21) [12], mercaptoethanol [13].
Experiments of bilitranslocase inactivation/reactivation were
performed in two-steps: prior incubation and transport assay.
Step 1 : prior incubation. 123 mg protein/ml vesicles, 33 mM
Hepes, pH 7.4, 133 mM NaCl; unless otherwise specified in the
figure legends, the inhibitor was 0.15 mM p-hydroxymercuri-
benzoate; this reaction mixture was kept at 37°C; further manip-
ulations are described in the figure legends; aliquots thereof
were transferred into the assay system. Step 2: transport assay.
Bilitranslocase activity was assayed by the spectrophotometric
technique previously described, enabling the continuous record-
ing of sulfobromophthalein movements into vesicles, monitored
at the wavelength pair 580 nm2514.4 nm [2]. The test was car-
ried out by the addition of 6210 ìl of previously incubated vesi-
cles to a cuvette, containing 2 ml assay medium (0.1M potas-
sium phosphate, pH 8.0, 39 ìM sulfobromophthalein), under
stirring conditions, at room temperature. 4 s later, when no net
sulfobromophthalein movement is detected, further sulfobromo-
phthalein entry into vesicles was driven by the K1 diffusion po-
tential generated by the injection of 10 ìg valinomycin (Fluka,
Fig.1. Substrate concentration dependence of electrogenic sulfobro-dissolved in 10 ìl methanol) into the cuvette. The initial, linear
mophthalein uptake rate in plasma membrane vesicles under dif-absorbance drop lasts nearly 1 s and is the measure of bilitrans-
ferent conditions. Experimental conditions. Prior incubation: vesicleslocase transport activity [2, 6]. (3.5 mg protein/ml) were incubated as described in Materials and Meth-Conditional for the correct understanding of the results is an ods, in the absence (d) or in the presence of either 0.15 mM p-hydro-
appreciation that the prior incubation and the transport steps are xymercuribenzoate (s) or 10 mM methylglyoxal (,). Transport assay:
totally separated. On account of the following facts: (a) 100- 4.3 ìl of incubated vesicles were put into 2 ml assay medium containing
fold dilution of all components of the mixture in the assay cu- variable sulfobromophthalein (BSP) concentrations. The assay was car-
ried out as described in Material and Methods. Data were fitted to thevette; (b) temperature shift ; (c) time scale of the second step
Michaelis-Menten equation. Parameters: Vmax 5 28.860.9 ìmol min21(, 5 s) compared with the first one (minutes), any chemical re-
mg21 protein21; Km 5 5.3260.63 ìM (filled symbols); Vmax 5action occurring in the prior incubation step is halted in the assay
28.860.8 ìmol min21 mg21 protein; Km 5 37.3562.4 ìM (open sym-step ; conversely, the addition of the sample to the assay cuvette
bols). Inset : Double-reciprocal plot of the two data sets. Data were fitted
virtually does not change the assay-medium composition. Inde- by linear regression analysis.pendent, preliminary control experiments (data not shown) were
carried out to check the validity of these statements. A system-
atic control is, however, displayed in the figures as the time zero
value, when the transport activity of the complete mixture is and, in addition, the system still transports (with unaltered Vmax),
a ternary complex (inhibitor-carrier-sulfobromophthalein) is toassayed, and all other data points obviously refer to variations
thereof. be postulated. This is reminiscent of type Ib competitive inhibi-
tion, according to Dixon and Webb [15].Protein determination was carried out by the Bradford
method [14]. All other chemicals were of the highest purity These results provide the explanation for the apparent half-
maximal inactivation following modification of either the Nbs2-commercially available.
Data were analyzed by the mathematical tools offered by the sensitive cysteine(s) [7, 8] or the arginine(s) [9] previously re-
ported. The routine substrate concentration used in the bilitrans-SigmaPlot program (Jandel Scientific Software GmbH).
locase transport assay is 39 ìM. Under these conditions, the na-
tive carrier operates close to Vmax. In contrast, the data of Fig. 1
show that the modified carrier acts just in the range of its half-RESULTS
maximal velocity. A corollary of this situation is that 50 % inhi-
bition of the carrier activity (under strictly fixed assay condi-Transport kinetics of native and chemically modified bili-
translocase. The concentration dependence of the initial rate of tions) implies that all the carrier molecules in the sample are
combined with the inhibitor. This offers an experimental tool tosulfobromophthalein entry into vesicles was examined in the na-
tive, the cysteine-modified and the arginine-modified carrier. Se- titrate the actual percentage of the modified carrier, C-I (i.e.
50 % transport activity 5 100 % [C-I]; 100 % transport activ-lective modification of the 5,5′-dithio-bis(2-nitrobenzoate)
(Nbs2)-sensitive class of cysteines is achieved also with p-hy- ity 5 0 % [C-I]).
The unavoidable conclusion to be drawn from the data abovedroxymercuribenzoate, as previously reported [7, 8]. Results of
this experiment are shown in Fig. 1. Two saturation curves are is that, irrespective of the amino acid targeted (cysteine or argi-
nine) and also of the chemical nature of the reagents employedobtained, one for the control and the other for the modified
samples. Both data sets were fitted to the Michaelis-Menten (mercurials, disulfides, maleimides, dicarbonyls, etc.), only one
kinetic species appears, featured by a sevenfold higher Km value.equation. The Km values were found to be 5.3 ìM and 37.3 ìM
sulfobromophthalein for the native and the modified carrier, re- The electrogenic sulfobromophthalein entry into vesicles has
been shown to be partially inhibited also by the serine-specificspectively. In contrast, identical Vmax values were found for the
three forms of the carrier. The inset in Fig. 1 shows the double- reagent phenylmethylsulfonyl fluoride [16]. In this case, maxi-
mal inhibition is only by about 30 %. A kinetic investigation ofreciprocal plot, for a visual appreciation of this outcome. Kineti-
cally speaking, the chemical modification of these two types of the same kind as that shown in Fig. 1 revealed that phenyl-
methylsulfonyl fluoride affected only the maximal rate of trans-amino acid residues is indistinguishable from typical competi-
tive inhibition. Since we are dealing with irreversible inhibitors port (19.9 ìmol min21 mg protein versus 28.8 ìmol min21 mg
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Fig.3. Plot of C*-I, C* and C concentrations versus time. [C*-I] data
Fig. 2. Bilitranslocase reactivation induced by mercaptoethanol: ef- points (m) were obtained from the last data points of curves a, b, c and
fect of early removal of the reactivator. Experimental conditions. Prior d in Fig. 2. These were fitted to a single exponential decay. [C] data
incubation: vesicles were incubated with 0.15 mM p-hydroxymercuri- points (d) were obtained with 0.417 mM mercaptoethanol, as described
benzoate for 8 min before the addition of 0.417 mM mercaptoethanol in Fig. 2; they were fitted to Eqn (2) in the text. The curve describing
(s); 0.417 mM N-ethylmaleimide was added 20 (.), 30 (j), 40 (m) [C*] (dashed line) was computed as described in the text. Parameters:
and 80 (d) s later. Transport assay: as in Fig. 1 ; see also Materials and k1 5 2.10960.1689 min21 ; k2 5 0.17960.006 min21.
Methods. The reactivation curves were obtained by fitting data to third-
order regression.
at 30, 40 and 80 s, respectively. Clearly, the later mercapto-
ethanol was removed, the higher the ultimate recovery of C.
protein21), whereas the Km values were left much the same Particularly meaningful is curve d, which superposed with the(5.0 ìM and 5.32 ìM). It can therefore be concluded that control one, indicating that N-ethylmaleimide was not in excess,
phenylmethylsulfonyl fluoride inhibits bilitranslocase transport having reacted only with free mercaptoethanol while not with
activity by a different mechanism than that found with cysteine bilitranslocase cysteines. Another control (data not shown)
and arginine reagents. established that N-ethylmaleimide was not defective, since its
addition before mercaptoethanol, as expected, completely pre-
Complex bilitranslocase reactivation kinetics. Fig. 2 shows vented reactivation.
the kinetics of reactivation induced by mercaptoethanol to vesi- The last data points of each curve are a measure of the con-
cles pretreated with p-hydroxymercuribenzoate. Clearly, reacti- centration of the activated carrier, [C], at equilibrium. Since, at
vation occurs sigmoidally, as previously reported [8, 9]. This is those times of the experiment, [Ctot] 5 1 5 [C*-I] 1 [C], C con-
the typical time-course of a two-step, irreversible reaction, centration could be calculated from these data and plotted versus
which implies the formation of an intermediate before the ap- the time of N-ethylmaleimide addition. They fitted an exponen-
pearance of the final product [17]. It may be reasonably assumed tial decay equation, with a rate constant k1 5 2.1 min21.
therefore that such an intermediate is the free carrier, still dis-
playing a high Km for transport. We could denote this compound Disclosure of an intermediate C* in the bilitranslocase-reac-
as C*. This mechanism can be so described : tivation reaction. Taking k1 5 2.1 and fitting the reactivation
data points to Eqn (2), k2 was found to be 0.18 min21. Then,
C* 2 I ——→k1 C* 1 I ——→k2 C 1 I . (1) given that at any time [Ctot] 5 15 [C*-I] 1 [C*] 1 [C], by
difference [C*] can be calculated [17].If we call the two rate constants k1 and k2, the kinetics of C Fig. 3 collates the time-course of the concentration changesappearance can be described by the following equation [17]:
of all three forms of the carrier, i.e. C*-I, C* and C. C* appears
[C] 5 [C* 2 I] {11 [1/(k1 2 k2)] [k2e(2k1t) 2 k1 e(2k2t)]} . as a transient intermediate, that rises steeply to a considerably
(2) high concentration and then slowly decays to C.
Effect of substrates on the rate of C*-to-C conversion. OurKinetics of mercurial displacement from bilitranslocase. The
other curves of Fig. 2 derive from an experiment designed to next target was to characterize the reported rate-enhancing effect
of bilitranslocase ligands on the reactivation kinetics [8, 9]. Themeasure the rate of C*-I disappearance. Mercaptoethanol was
added to vesicles previously incubated with the mercurial, in effect of sulfobromophthalein on the reactivation rate was there-
fore examined. The conditions of the experiment were the sameorder to displace the inhibitor from the carrier and so induce its
reactivation. Curve a was obtained by adding a titrated amount as those of Fig. 2. It was chosen to add the substrate 1.5 min
after the addition of mercaptoethanol, because at that time theof N-ethylmaleimide 20 s after the addition of mercaptoethanol.
The addition results in the removal of mercaptoethanol, thus prevailing species of the carrier is C*, and the appearance of C
is obviously related to only k2. Fig. 4A shows that sulfobro-stopping the first of the two consecutive reactions written in
Eqn (1). Since, under these conditions, only a fraction of C*-I mophthalein enhances the reactivation rate in a concentration-
dependent manner. Fig. 4 B is a plot of k2 versus sulfobromo-could be converted to C*, only an equivalent fraction of C could
be recovered at the end. Curves b, c and d were obtained in the phthalein concentration. The data fit a hyperbolic function, with
a limiting value of 1.9 min21 and a half-saturation value ofsame way, but N-ethylmaleimide was added at later times, i.e.
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Fig. 4. Effect of sulfobromophthalein on the rate of mercapto-
ethanol-induced conversion to the high-affinity conformer of bilit-
ranslocase. (A) Time-course of the conversion. (B) Dependence of
the C*-to-C conversion rate constant (k2) upon sulfobromophthalein
concentration. (A) Experimental conditions. Prior incubation: vesicles
were incubated with 0.15 mM p-hydroxymercuribenzoate for 8 min be-
Fig.5. Time-course of C*-I disappearance induced by mercapto-fore the addition of 0.417 mM mercaptoethanol; increasing sulfobro-
ethanol: effect of sulfobromophthalein. C*-I concentrations in the ab-mophthalein concentrations were added 1.5 min later ; for clarity, reacti-
sence of sulfobromophthalein (s) were obtained from the last datavation time-courses are shown for only the following conditions: control
points of curves a, b, c and d in Fig. 3. Corresponding values in the(d), 4.69 (s), 7.03 (h), 14.06 (n) and 112.5 (,) ìM sulfobromophthal-
presence of 26.2 ìM sulfobromophthalein (d) were obtained as de-ein. Transport assay: see Materials and Methods. Curves were obtained
scribed in the text. The pooled data were fitted to a single exponentialby taking k1 5 2.1 min21 and fitting data to Eqn (2) in the text and re-
decay (k1 5 2.05060.0951 min21). Other details as in Fig. 2.spective k2 values were found. (B) Plot of k2 versus [sulfobromophthal-
ein]; data were fitted to the equation : k2 5 [k2max[sulfobromophthalein]/
(Kd 1 [sulfobromophthalein])] 1 k0, where k0 is the conversion rate con-
stant in the absence of substrates (0.245060.0157 min21); parameters:
k2max 5 1.87760.122 min21 ; Kd 5 37.6866.18 ìM sulfobromophthal-
ein.
37.7 ìM. From all of these data it can be concluded that the
enhancing effect of sulfobromophthalein on the reactivation rate
is certainly due to a specific acceleration of the transition from
the low-affinity to the high-affinity state of the carrier. The half-
saturation value is a measure of the dissociation constant of the
C*-sulfobromophthalein complex, which is virtually the same as
the Km value of the modified carrier (37.3 ìM) already found.
The effect of nicotinic acid on the reactivation rate was ex-
amined in an experiment designed exactly as the previous one.
This ligand was chosen because, like sulfobromophthalein, it is
freely soluble in water. Based on previous research [16], nico-
tinate is to be regarded as the strictest and the simplest func-
tional analogue of bilirubin. From the data obtained (not shown),
the dissociation constant of the C*-nicotinate complex was
Fig.6. Time-course of the bilitranslocase high-affinity form disap-found to be 78.6 nM, which is higher than that of the C-nicoti-
pearance induced by p-hydroxymercuribenzoate at 0°C and effectnate complex (11 nM, [16]) by, again, a factor of about seven.
of subsequent temperature jumps. Experimental conditions. Prior in-
cubation: vesicles (2.82 mg protein/ml) were incubated in ice withTesting the effect sulfobromophthalein on the rate of mercu- 0.15 mM p-hydroxymercuribenzoate; samples (3 ìl) were then assayed
rial displacement from bilitranslocase. To establish whether for transport activity (s); aliquots were diluted with 5 volumes of buffer
the substrates enhance the reactivation rate also by modulating (33 mM Hepes, pH 7.4, 135 mM NaCl) at 37°C and incubated at this
k1, the rate of C*-I disappearance in the presence of sulfobro- temperature later on. Samples (18 ìl, 0.47 mg protein/ml, 0.025 mM p-
mophthalein was measured. The experimental design was the hydroxymercuribenzoate) were then assayed for transport activity (d).
Transport assay : see Materials and Methods. Data were fitted to singlesame as that reported in Fig. 2, but mercaptoethanol addition
exponential decays: inactivation rate constant at 0°C and 0.15 mM p-was preceded by the addition of 26.2 ìM sulfobromophthalein.
hydroxymercuribenzoate 5 0.56531023 min21; inactivation rate con-Fig. 5 is the plot of the pooled data obtained either in the pres-
stants at 37°C and 0.025 mM p-hydroxymercuribenzoate (pooledence or in the absence of sulfobromophthalein. Under both con-
data) 5 0.0677 min21.ditions, C*-I disappearance can be described by a common,
single exponential, with much the same rate constant as deter-
mined before (2.05 min21). These data enable us to conclude following cysteine (or arginine) restoration. As to the mecha-
that the substrate rate-enhancing effect is solely due to the mod- nism of the carrier inhibition, the above results allow to envisage
ulation of k2. two alternative pathways:
(A) C 1 I → C 2 I → C*-IPathways to bilitranslocase inhibition. The data shown so far
provide a mechanism for the reactivation of bilitranslocase (B) C ↔ C* ; C* 1 I → C*-I .
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Vesicles treated with p-hydroxymercuribenzoate, were exposed
to mercaptoethanol under a number of experimental conditions.
At the onset of the experiment, C concentration was close to
0, i.e. all the carrier was in the C*-I form. Upon addition of
mercaptoethanol, C appeared. Filled circles describe the rate of
C formation at 37°C. All other curves start 1 min after the addi-
tion of the thiol. At this time, it was experimentally measured
(data not shown) that the carrier forms were: C*-I 5 15 %; C*5
75 %; and C 5 10 %. An aliquot was chilled with 3 vol. of ice-
cold buffer and kept in ice thereafter. The open circles (Fig. 7)
describe the rate of C formation under this condition (at later
times, the reaction was speeded up by heating the sample at
37°C, open squares). The filled triangles (Fig. 7) show that p-
hydroxymercuribenzoate added to an identical sample blocked
the conversion to C. As expected, mercaptoethanol, added later,
induced C formation (Fig. 7, open triangles). The specific inhibi-
tory effect of the mercurial observed at 0°C shows that C*, the
prevailing form in this experiment, can react at a significant rate
at a low temperature. Note that C does not have the same prop-
erty, as shown by the experiment reported in Fig. 6.Fig. 7. Time-course of the bilitranslocase high-affinity form appear-
Taken together, these results (Figs 6 and 7) allow us to con-ance induced by mercaptoethanol and effect of early addition of p-
clude that the most reactive species towards the sulfhydryl re-hydroxymercuribenzoate. Experimental conditions. Prior incubation :
vesicles (2.82 mg protein/ml) were incubated with 0.15 mM p-hydro- agent is C* rather than C. It follows reasonably that both C and
xymercuribenzoate at 37°C for 10 min; the experiment starts with the C* co-exist in the membrane and the latter is trapped by cova-
addition of 0.41 mM mercaptoethanol; samples (3 ìl) were assayed for lent modification, thus shifting the equilibrium to the right.
transport activity (d); after 1min at 37°C, two aliquots were with- These data show, in addition, that the covalent modifications on
drawn: aliquot A was diluted with 3 vol. of ice-cold buffer (33 mM the cysteine(s) or the arginine(s), per se, are devoid of functionalHepes pH 7.4, 135 mM NaCl), kept in ice and samples (12 ìl, 0.7 mg
effects on bilitranslocase.protein/ml, 0.065 mM excess mercaptoethanol) tested for transport activ-
ity (s); at 41min, this aliquot was transferred to 37°C (h); aliquot B
was treated like aliquot A, but the ice-cold dilution buffer was supple-
mented with 0.287 mM p-hydroxymercuribenzoate; samples (12 ìl, DISCUSSION
0.7 mg protein/ml, 0.15 mM excess p-hydroxymercuribenzoate) were
tested for transport activity (m); aliquot B′ was withdrawn from aliquot There is little doubt that sulfobromophthalein moves in iso-
B, added with 0.41 mM mercaptoethanol and tested for transport activity lated, intact hepatocytes in a rheogenic manner [18]. This con-(n). clusion has been reached on the basis of the observation that the
distribution of the anion across the cell is influenced by the pres-
ence or absence of a physiological membrane potential. It shouldPathway (A) implies that the conversion to C* is necessarily be concluded therefore that an electrogenic carrier has to play apreceded by either cysteine or arginine derivatization. Alterna- key role in the process. A substantial amount of experimentaltively, pathway (B) implies both that C* is the specific target data has been collected, demonstrating that bilitranslocase canof the inhibitors and that it occurs in the native membrane in be such a carrier: firstly, the reconstituted system obtained with
equilibrium with C. To discriminate between the two models, proteoliposomes containing purified bilitranslocase operatesexperiments reported below have been carried out.
electrogenically, in that the movement of the dye can be effi-
ciently driven by a membrane potential [4]; secondly, in plasmaTesting the reaction of p-hydroxymercuribenzoate with C.
membrane vesicles, electrogenic sulfobromophthalein transportFig. 6 shows the results of an experiment in which plasma mem-
can be demonstrated with a sensitive spectrophotometric assaybrane vesicles were incubated at 0 °C with p-hydroxymercuri-
[2] and immunochemical studies have allowed the identificationbenzoate. At different time intervals samples from the suspen-
of the carrier responsible for this electrogenic movement withsion were brought to 37°C. Such a temperature jump was at-
bilitranslocase [6].tained by sixfold dilution of the samples with pre-heated buffer.
This assay has been so designed that the measurement isIt should be stressed that in this way the inhibitor concentration
taken after the system has spontaneously equilibrated, so thatwas lowered accordingly. Open circles indicate that C concentra-
the phthalein has reached its electrochemical equilibrium beforetion did not appreciably decline during 45 min prior incubation
the imposition of a membrane potential. The latter representsin ice. Two possible explanations are conceivable : either the
therefore the only driving force to the transport. It follows that,mercurial did not appreciably react with cysteine(s), or, alterna-
under these conditions, electroneutral movements cannot be de-tively, the conformational change converting C-I to C*-I (see
tected, by definition. This eliminates the possible contribution topathway A) did not take place at all. However, raising the tem-
the measure of other sulfobromophthalein carriers, responsibleperature at any time resulted in the disappearance of C at a rate
for this type of transport, notably organic-anion-transportingindependent of the length of the prior incubation time. Note that
polypeptide (oatp) [19]. This carrier has been claimed to carrythis rate was exactly the same as that found at time 0. Had C-I
out electroneutral organic anion transport [20, 21]. However, theconcentration increased along the time, a proportional increase
physiological substrate of oatp is taurocholate, which, in thisof the rates should have been detected. The latter supports the
case, is transported by a sodium-independent mechanism [22].concept that C does not react with the mercurial at an any appre-
A consistent observation is that taurocholate, either in the pres-ciable rate at 0°C.
ence or in the absence of sodium, exerts no inhibition at all on
the spectrophotometrically recorded electrogenic sulfobromo-Testing the reaction of p-hydroxymercuribenzoate with C*.
The results of a reactivation experiment are shown in Fig. 7. phthalein transport in rat liver plasma membrane vesicles [23],
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clearly indicating that bile acid carriers take no part in the mea- under different metabolic conditions, normally producing no ap-
preciable change in bilirubinemia, jaundice may appear. Typi-surement. The involvement of other electrogenic sulfobromo-
phthalein carriers cannot, in principle, be discounted. Evidence cally, such a situation is found in Gilbert’s subjects [25]. On a
number of occasions, it has been pointed out that the syndromein this sense is, however, still missing. An additional point to be
raised concerns the type of the physical measurement carried is accompanied by an impairment of the clearance of a number
of organic anions [26]. Most of these, though, are not glucurono-out. Spectrophotometry offers the advantage over other tech-
niques usually employed in the study of membrane transports, conjugated, which rules out the direct involvement of the dem-
onstrated genetic defect of glucuronyl transferase [27], as theof being a continuous one, allowing us to follow rapid kinetics
and giving a complete picture of events rather than discrete basis of this additional feature of Gilibert’s syndrome. It has
been proposed that bilitranslocase could also be defective in Gil-points at different times [24]. Only under these conditions can a
sound kinetic analysis be performed with acceptable experimen- bert’s subjects [28, 29] and the pathogenetic mechanism could
be that suggested above. These possibilities are currently undertal confidence.
Further support for the concept that only one carrier, i.e. investigation by our group.
The obvious possibility is still open that C* and C may evenbilitranslocase, is being measured by the spectrophotometric
assay is provided by the data here reported : the partial inhibition be components along the translocation pathway. A quite dif-
ferent experimental set-up is needed to test this point [30].of sulfobromophthalein transport by cysteine-modifying or argi-
nine-modifying reagents can be perfectly accounted for by the
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